AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

The9 Limited

$3.8 -$2.43 (-39.00%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$4.18
Day Range
$3.77$4.11
Year Range
$3.14$11.6
Market Cap
57.86M
AVG Volume
148.43K
Trailing/Forward PE
1.75/-
PEG ratio
0.02
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
NASDAQUS
Revenue (CNY)
025M50M75M100M21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Revenue (CNY) by quarter
PeriodRevenue (CNY)
26 Q217.67M
25 Q444.99M
25 Q261.29M
24 Q419.96M
24 Q292.73M
23 Q482M
23 Q297.05M
22 Q462.58M
22 Q245.78M
21 Q410M
Net Income (CNY)
-750M-500M-250M0250M500M21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Net Income (CNY) by quarter
PeriodNet Income (CNY)
26 Q2377.68M
25 Q4-334.41M
25 Q2-68.04M
24 Q4-74.89M
24 Q2227.59K
23 Q4289.81M
23 Q2-269.81M
22 Q4-387.79M
22 Q2-599.31M
21 Q4-282.56M
Operating Income (CNY)
-300M-200M-100M021 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Operating Income (CNY) by quarter
PeriodOperating Income (CNY)
26 Q2-190.34M
25 Q4-179.45M
25 Q2-68.31M
24 Q4-109.5M
24 Q2-53.22M
23 Q4-37.33M
23 Q2-280.42M
22 Q4-167.28M
22 Q2-251M
21 Q4-250.39M
EBITDA (CNY)
-300M-200M-100M0100M21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY EBITDA (CNY) by quarter
PeriodEBITDA (CNY)
26 Q2-148.44M
25 Q4-25.07M
25 Q2-68.31M
24 Q4-48.03M
24 Q2-53.22M
23 Q414.64M
23 Q2-84.53M
22 Q4-77.61M
22 Q2-251M
21 Q4-219.51M
Cash Flows (CNY)
-600M-400M-200M0200M400M21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q426 Q2
NCTY Cash Flows (CNY) by quarter
PeriodCash Flows (CNY)
26 Q2-28.29M
25 Q4-33.2M
24 Q4-62.2M
24 Q20
23 Q40
23 Q20
22 Q4202.35M
22 Q20
21 Q4-456.06M
21 Q2-307.25M
EPS (CNY)
-300-200-100010021 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY EPS (CNY) by quarter
PeriodEPS (CNY)
26 Q236
25 Q4-21.39
25 Q2-11.82
24 Q4-14.4
24 Q20.06
23 Q417.31
23 Q2-90
22 Q4-150
22 Q2-267
21 Q4-132
Expenses (CNY)
0100M200M300MR&DSG&ACapex21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Expenses (CNY) by quarter
PeriodExpenses (CNY)
21 Q243.3M
26 Q280.76M
25 Q426.95M
25 Q267.03M
24 Q4118.86M
24 Q260.16M
23 Q473.3M
23 Q2133.52M
22 Q4131.32M
22 Q2240M
21 Q4243.15M
Cash & Debt (CNY)
0200M400M600MCashLong Term DebtShort Term Debt21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Cash & Debt (CNY) by quarter
PeriodCash & Debt (CNY)
26 Q212.72M
25 Q4310.89M
25 Q236.09M
24 Q410.91M
24 Q214.25M
23 Q445.22M
23 Q220.91M
22 Q458.06M
22 Q274.89M
21 Q4429.22M
Debt ratios
-1-0.500.5121 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Debt ratios by quarter
PeriodDebt ratios
26 Q2-0.69
25 Q40.39
25 Q2-0.81
24 Q4-0.73
24 Q2-0.55
23 Q4-0.07
23 Q2-0.12
22 Q4-0.03
22 Q20.01
21 Q40.91
Margins
-400%-200%0%200%21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Margins by quarter
PeriodMargins
26 Q226.52%
25 Q46.87%
25 Q2-2.09%
24 Q4-43.72%
24 Q27.58%
23 Q4-29.48%
23 Q2-8.94%
22 Q4-57.45%
22 Q2-24.01%
21 Q4-395.81%
Return on Capital
-1500%-1000%-500%0%500%21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Return on Capital by quarter
PeriodReturn on Capital
26 Q265.03%
25 Q4-137.79%
25 Q2-14.54%
24 Q4-17.52%
24 Q20.05%
23 Q4159.82%
23 Q2145.82%
22 Q4-1408.17%
22 Q2-195.86%
21 Q4-37.01%
Shares Outstanding
05M10M15M20M21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Shares Outstanding by quarter
PeriodShares Outstanding
26 Q210.55M
25 Q415.23M
25 Q25.73M
24 Q45.1M
24 Q24.25M
23 Q43.8M
23 Q22.95M
22 Q42.63M
22 Q22.17M
21 Q42.18M
Dividends (CNY)
0100200300400Jan 09
NCTY Dividends (CNY) by quarter
PeriodDividends (CNY)
Jan 09333
Employee Count
01002003004002016201720182019202020212022202320242025
NCTY Employee Count by quarter
PeriodEmployee Count
202544
202450
202350
202272
202174
202047
201961
2018105
2017236
2016354
Book Value Per Share (CNY)
-200020040021 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Book Value Per Share (CNY) by quarter
PeriodBook Value Per Share (CNY)
26 Q255.05
25 Q415.94
25 Q281.65
24 Q483.76
24 Q2102.65
23 Q447.72
23 Q2-62.64
22 Q410.45
22 Q2141.2
21 Q4350.53
Total Assets (CNY)
0500M1B1.5B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
NCTY Total Assets (CNY) by quarter
PeriodTotal Assets (CNY)
26 Q2993.08M
25 Q4594.13M
25 Q2713.32M
24 Q4636.64M
24 Q2667.75M
23 Q4363.73M
23 Q2352.75M
22 Q4599.11M
22 Q2776.84M
21 Q41.31B
PE Ratio
050100150med 2.7Mar 21Jul 21Oct 21Feb 22Sep 25Dec 25Apr 26
NCTY PE Ratio by quarter
PeriodPE Ratio
Apr 261.36
Apr 261.45
Mar 261.43
Mar 261.43
Mar 261.57
Mar 261.55
Feb 261.5
Feb 261.37
Feb 261.52
Feb 261.58
Jan 261.71
Jan 262.02
Jan 261.85
Jan 261.8
Jan 261.7
Dec 251.92
Dec 252.25
Dec 252.03
Dec 251.98
Nov 251.98
Nov 251.94
Nov 251.81
Nov 252.09
Oct 252.66
Oct 252.71
Oct 252.36
Oct 252.57
Oct 252.85
Sep 252.81
Sep 252.75
Sep 252.86
Sep 252.68
Aug 252.54
Apr 221.3
Apr 221.39
Apr 221.48
Apr 221.47
Apr 221.58
Mar 221.7
Mar 221.84
Mar 221.6
Mar 221.73
Feb 221.96
Feb 222.1
Feb 222.26
Feb 222.23
Jan 222.09
Jan 222.5
Jan 223.09
Jan 223.08
Dec 213.52
Dec 214.28
Dec 214.41
Dec 214.13
Dec 214.39
Nov 215.45
Nov 216.2
Nov 216.66
Nov 215.52
Oct 215.96
Oct 215.58
Oct 215.81
Oct 215.99
Oct 215.82
Sep 212.24
Sep 212.69
Sep 212.9
Sep 213.49
Aug 213.3
Aug 213.07
Aug 213.26
Aug 213.11
Jul 212.46
Jul 211.91
Jul 212.16
Jul 212.55
Jul 212.83
Jun 212.95
Jun 213.62
Jun 214.21
Jun 212.86
May 212.54
May 212.76
May 213.37
May 213.85
Apr 215.06
Apr 214.68
Apr 214.62
Apr 215.94
Apr 217.59
Mar 2160.76
Mar 2189.53
Mar 21106.86
Mar 2170.58
Feb 2157.32
Feb 21144.93
Feb 2168.78
Feb 2140.9
Jan 2126.77
Jan 2119.63
Free Cash Flow Yield
-400%-200%0%200%med 39.89%Dec 23Mar 24Jun 24Oct 24Jan 25May 25Aug 25
NCTY Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Aug 25-20.13%
Aug 25-22.51%
Aug 25-19.77%
Aug 25-19.65%
Jul 25-18.62%
Jul 25-16.79%
Jul 25-17.77%
Jul 25-19.52%
Jun 25-22.24%
Jun 25-20.99%
Jun 25-20.35%
Jun 25-17.19%
May 25-18.09%
May 25-14.93%
May 25-14.08%
May 25-14.14%
May 25-13.63%
Apr 2553.68%
Apr 2563.94%
Apr 2564%
Apr 2554.57%
Mar 2546.95%
Mar 2553.43%
Mar 2556.6%
Mar 2555.11%
Feb 2557.95%
Feb 2539.86%
Feb 2543.46%
Feb 2542.11%
Jan 2542.06%
Jan 2541.46%
Jan 2538.75%
Jan 2543.86%
Jan 2539.92%
Dec 2441.52%
Dec 2443.64%
Dec 2437.43%
Dec 2434.46%
Nov 2444.56%
Nov 2459.4%
Nov 2459.1%
Nov 2478.94%
Nov 2481.12%
Oct 2479.97%
Oct 2474.65%
Oct 2478.33%
Oct 24103.88%
Sep 2499.12%
Sep 24103.87%
Sep 2497.26%
Sep 2497.2%
Aug 2494.56%
Aug 2499.8%
Aug 2499.77%
Aug 24129.02%
Aug 24102.02%
Jul 24101.45%
Jul 2487.84%
Jul 2480.18%
Jul 2482.32%
Jun 2483.94%
Jun 2492.83%
Jun 2486.55%
Jun 2487.06%
May 24104.61%
May 2490.78%
May 24105.92%
May 24110.65%
May 2495.4%
Apr 24106.2%
Apr 24120.97%
Apr 24-194.89%
Apr 24-185.84%
Mar 24-175.06%
Mar 24-224.18%
Mar 24-223.55%
Mar 24-223.02%
Mar 24-217.42%
Feb 24-217.84%
Feb 24-191.99%
Feb 24-198.03%
Feb 24-211.38%
Jan 24-208.16%
Jan 24-255.7%
Jan 24-204.53%
Jan 24-171.87%
Dec 23-161.57%
Dec 23-137.34%
Dec 23-161.11%
Dec 23-176.57%
Dec 23-143.07%
Nov 23-180.95%
Nov 23-182.69%
Nov 23-151.08%
Nov 23-195.76%
Oct 23-227.06%
Oct 23-327.97%
Oct 23-284.02%
Oct 23-304.78%
Sep 23-173.01%
Price to Sales
0.511.522.53med 1.33Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
NCTY Price to Sales by quarter
PeriodPrice to Sales
Sep 261.87
Sep 262.06
Sep 262.31
Aug 262.17
Aug 262.7
Aug 262.15
Aug 262.21
Jul 262.09
Jul 261.51
Jul 261.83
Jul 262.04
Jul 262.4
Jun 262.41
Jun 262.33
Jun 262.22
Jun 262.21
May 262.47
May 262.51
May 262.68
May 262.74
May 262.65
Apr 262.69
Apr 262.56
Apr 260.78
Apr 260.83
Mar 260.82
Mar 260.82
Mar 260.9
Mar 260.89
Feb 260.86
Feb 260.79
Feb 260.87
Feb 260.91
Jan 260.98
Jan 261.16
Jan 261.07
Jan 261.03
Jan 260.98
Dec 251.1
Dec 251.3
Dec 251.17
Dec 251.14
Nov 251.14
Nov 251.12
Nov 251.04
Nov 251.2
Oct 251.53
Oct 251.56
Oct 251.36
Oct 251.48
Oct 251.64
Sep 251.61
Sep 251.58
Sep 251.64
Sep 251.54
Aug 251.46
Aug 251.06
Aug 250.95
Aug 251.08
Aug 251.08
Jul 251.14
Jul 251.27
Jul 251.2
Jul 251.09
Jun 250.96
Jun 251.02
Jun 251.05
Jun 251.24
May 251.18
May 251.43
May 251.51
May 251.51
May 251.56
Apr 251.13
Apr 250.95
Apr 250.95
Apr 251.11
Mar 251.29
Mar 251.13
Mar 251.07
Mar 251.1
Feb 251.04
Feb 251.52
Feb 251.39
Feb 251.44
Jan 251.44
Jan 251.46
Jan 251.56
Jan 251.38
Jan 251.52
Dec 241.46
Dec 241.39
Dec 241.62
Dec 241.76
Nov 241.36
Nov 241.02
Nov 241.02
Nov 240.77
Nov 240.75
Oct 240.76
Price/Operating Cashflow
0246med 1.77Jan 20Apr 20Jun 24Sep 24Nov 24Feb 25Apr 25
NCTY Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Apr 251.86
Apr 251.56
Apr 251.56
Apr 251.83
Mar 252.13
Mar 251.87
Mar 251.77
Mar 251.81
Feb 251.73
Feb 252.51
Feb 252.3
Feb 252.37
Jan 252.38
Jan 252.41
Jan 252.58
Jan 252.28
Jan 252.5
Dec 242.41
Dec 242.29
Dec 242.67
Dec 242.9
Nov 242.24
Nov 241.68
Nov 241.69
Nov 241.27
Nov 241.23
Oct 241.25
Oct 241.34
Oct 241.28
Oct 240.96
Sep 241.01
Sep 240.96
Sep 241.03
Sep 241.03
Aug 241.06
Aug 241
Aug 241
Aug 240.78
Aug 240.98
Jul 240.99
Jul 241.14
Jul 241.25
Jul 241.21
Jun 241.19
Jun 241.08
Jun 241.16
Jun 241.15
May 240.96
May 241.1
May 240.94
May 240.9
May 241.05
Apr 240.94
Apr 240.83
Apr 202.47
Apr 202.18
Apr 202.13
Apr 202
Mar 202.05
Mar 201.91
Mar 201.93
Mar 203.16
Feb 203.38
Feb 204.72
Feb 204.5
Feb 204.56
Jan 204.43
Jan 204.52
Jan 204.65
Jan 204.88
Jan 205.1
Price to Book
0123med 0.83Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
NCTY Price to Book by quarter
PeriodPrice to Book
Sep 260.46
Sep 260.51
Sep 260.57
Aug 260.54
Aug 262.44
Aug 261.94
Aug 261.99
Jul 261.89
Jul 261.36
Jul 261.65
Jul 261.84
Jul 262.16
Jun 262.17
Jun 262.1
Jun 262
Jun 261.99
May 262.23
May 262.26
May 262.42
May 262.47
May 262.39
Apr 262.42
Apr 262.31
Apr 260.43
Apr 260.46
Mar 260.45
Mar 260.45
Mar 260.49
Mar 260.49
Feb 260.47
Feb 260.43
Feb 260.48
Feb 260.5
Jan 260.54
Jan 260.64
Jan 260.58
Jan 260.57
Jan 260.53
Dec 250.6
Dec 250.71
Dec 250.64
Dec 250.62
Nov 250.62
Nov 250.61
Nov 250.57
Nov 250.66
Oct 250.83
Oct 250.85
Oct 250.74
Oct 250.81
Oct 250.9
Sep 250.88
Sep 250.86
Sep 250.9
Sep 250.84
Aug 250.8
Aug 250.72
Aug 250.65
Aug 250.74
Aug 250.74
Jul 250.78
Jul 250.87
Jul 250.82
Jul 250.75
Jun 250.65
Jun 250.69
Jun 250.71
Jun 250.85
May 250.8
May 250.97
May 251.03
May 251.03
May 251.07
Apr 250.86
Apr 250.73
Apr 250.72
Apr 250.85
Mar 250.99
Mar 250.87
Mar 250.82
Mar 250.84
Feb 250.8
Feb 251.16
Feb 251.07
Feb 251.1
Jan 251.1
Jan 251.12
Jan 251.2
Jan 251.06
Jan 251.16
Dec 241.12
Dec 241.06
Dec 241.24
Dec 241.35
Nov 241.04
Nov 240.78
Nov 240.78
Nov 240.59
Nov 240.57
Oct 240.58
The9 Limited
NCTY
Stockpicker

Video analysis: NCTY

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: NCTY

The9 Q2 Earnings Call Highlights

marketbeat.com · 24 Aug 2026

The9 Q2 Earnings Call Highlights

The9 NASDAQ: NCTY reported second-quarter net income of $32 million, up more than 39% from the prior quarter, as the company advanced its repositioning around The9bit, an AI-powered game creation platform supported by a token-based ecosystem.

The9 Reports US$32 Million Net Income for Second Quarter of 2026, Up Over 39% Sequentially

prnewswire.com · 24 Aug 2026

The9 Reports US$32 Million Net Income for Second Quarter of 2026, Up Over 39% Sequentially

Increase driven by the fair-value recognition of 9BIT tokens received under the Company's cooperation agreement with the 9BIT Foundation as the9bit continued to expand AI capabilities, community engagement and commercial partnerships SHANGHAI, Aug. 24, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global, diversified high-tech company, today reported its unaudited financial results for the three months ended June 30, 2026. Second Quarter 2026 Highlights Strong sequential growth: Net income for the quarter was US$32 million, an increase of more than 39% from the previous quarter.

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

gurufocus.com · 21 Aug 2026

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

prnewswire.com · 21 Aug 2026

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

Milestone Marks Further Progress in The9's Strategic Investment in AI-Driven Drug Discovery; The9 Expects to Hold Approximately 15% to 16% of the Combined, Nasdaq-Listed Company SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global, diversified high-tech company, today announced that Nanyang Biologics Pte. Ltd. ("NYB"), a Singapore-based, AI-driven drug discovery company in which The9 holds a strategic equity stake, has taken a significant step toward its planned Nasdaq listing.

The9 Limited to Report Second Quarter 2026 Results on August 24, 2026

prnewswire.com · 17 Aug 2026

The9 Limited to Report Second Quarter 2026 Results on August 24, 2026

SHANGHAI, Aug. 17, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global, diversified high-tech company, today announced that it will report its unaudited consolidated results for the second quarter ended June 30, 2026, before the U.S. market opens on Monday, August 24, 2026. The Company will host a conference call on Monday, August 24, 2026 at 8:30 PM Hong Kong Time (8:30 AM U.S. Eastern Time) to discuss the results.

The9 Investee Nanyang Biologics (NYB) Advancing Planned Nasdaq Listing for the US$1.5 Billion Business Combination

prnewswire.com · 11 Aug 2026

The9 Investee Nanyang Biologics (NYB) Advancing Planned Nasdaq Listing for the US$1.5 Billion Business Combination

NYB Obtained Notice of Effectiveness from SEC for Its Form F-4 Registration Statement The9 expects to own 15% to 16% of the combined company following NYB listing HONG KONG, Aug. 11, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global diversified high-tech company, today announced that its Singapore investee Nanyang Biologics Pte. Ltd. ("NYB") obtained the notice of effectiveness from the U.S. Securities and Exchange Commission for its Form F-4 registration statement filed in connection with the previously announced business combination, a key milestone toward NYB's planned listing on Nasdaq under the reserved ticker symbol "NYB.

The9 Expands Brand Partnership Network Across Southeast Asia

prnewswire.com · 6 Aug 2026

The9 Expands Brand Partnership Network Across Southeast Asia

the9bit Signs 41 Brand Partners Across Indonesia, Malaysia, and Vietnam, with 127 More in the Pipeline SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global diversified high-tech company, today announced continued progress in the Southeast Asia offline-to-online ("O2O") initiative of the9bit, its AI-powered digital asset ecosystem. The initiative has built a growing network of brand partnerships across Indonesia, Malaysia, and Vietnam as part of a strategy of integrating digital entertainment experiences with physical retail environments.

The9 Posts Record Quarterly Profit; Expects Sequential Growth Through 2026

gurufocus.com · 27 Jul 2026

The9 Posts Record Quarterly Profit; Expects Sequential Growth Through 2026

The9 Posts Record Quarterly Profit; Expects Sequential Growth Through 2026 PR Newswire SHANGHAI, July 27, 2026

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.